Received May 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPA | HEP A (HAVRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
Pediatric dose administered to an adult patient; Pediatric dose administered to an adult patient; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of adult use of a child product in a 64-year-old female patient who received HAV (Havrix pediatric) for prophylaxis. On 12-MAY-2026, the patient received the 1st dose of Havrix pediatric. On 12-MAY-2026, an unknown time after receiving Havrix pediatric, the patient experienced adult use of a child product (Verbatim: Pediatric dose administered to an adult patient) and underdose (Verbatim: Pediatric dose administered to an adult patient). The outcome of the adult use of a child product and underdose were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 12-MAY-2026 Pharmacist called to report that they administered a pediatric dose of Havrix to a 64 years old patient. The administration date was today 12-MAY-2026. The reporter need advice on what do they have to do next. The batch number was not provided upon follow up with the reporter.